Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Consensus Target Price of $56.00 According to Brokerages

Shares of Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) have been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $53.00.

A number of research analysts have recently issued reports on the stock. Guggenheim initiated coverage on shares of Cyclerion Therapeutics in a report on Monday, September 28th. They set a “buy” rating and a $70.00 price objective for the company. UBS Group assumed coverage on shares of Cyclerion Therapeutics in a report on Friday, September 11th. They issued a “buy” rating and a $55.00 target price on the stock. Stifel Nicolaus started coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They set a “buy” rating and a $43.00 price target for the company. Zacks Research upgraded Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a report on Friday, July 24th.

Cyclerion Therapeutics Price Performance

Shares of KRSA stock opened at $33.92 on Friday. The firm has a market cap of $22.73 million, a price-to-earnings ratio of -2.92 and a beta of 1.72. Cyclerion Therapeutics has a 12 month low of $7.19 and a 12 month high of $59.36.

Institutional Investors Weigh In On Cyclerion Therapeutics

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Cyclerion Therapeutics in the 2nd quarter valued at $57,000. Braidwell LP purchased a new position in Cyclerion Therapeutics during the 2nd quarter worth $532,000. Finally, ADAR1 Capital Management LLC purchased a new position in Cyclerion Therapeutics during the 2nd quarter worth $1,013,000. Institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease.